ADC Therapeutics
ADCT
Market cap $199M

2.06 USD

+0.03

1.48%

Updated Dec 26, 2:03 PM EST

1 day

1.48%

5 days

5.64%

1 month

-7.21%

3 months

-31.33%

6 months

-23.42%

Year to date

21.89%

1 year

24.85%

5 years

-93.05%

10 years

-93.05%

About: ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212.

Employees: 274

Healthcare Pharmaceutical Preparations

Funds holding %

of 6,809 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

191% more repeat investments, than reductions

Existing positions increased: 32 | Existing positions reduced: 11

141% more call options, than puts

Call options by funds: $265K | Put options by funds: $110K

19% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 16

4% more funds holding

Funds holding: 75 [Q2] → 78 (+3) [Q3]

0% less capital invested

Capital invested by funds: $173M [Q2] → $173M (-$181K) [Q3]

0.17% less ownership

Funds ownership: 56.94% [Q2] → 56.76% (-0.17%) [Q3]

33% less funds holding in top 10

Funds holding in top 10: 3 [Q2] → 2 (-1) [Q3]

See Fund Rankings

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

191%

upside

Avg. target

288%

upside

High target

$10

385%

upside

2 analyst ratings

2 positive

100%

0 neutral

0 negative

Guggenheim Michael Schmidt 26% 1-year accuracy 5 / 19 met price target	385%upside $10	Buy Reiterated	12 Dec 2024
Stephens & Co. Sudan Loganathan 21% 1-year accuracy 4 / 19 met price target	191%upside $6	Overweight Initiated	8 Nov 2024

See Analyst Rankings

Financial journalist opinion

Based on 5 articles about ADCT published over the past 30 days

Positive

Seeking Alpha

2 weeks ago

ADC Therapeutics: Continues To Make Strides With ZYNLONTA Targeting DLBCL

Initial positive results released from the phase 1b study, using ZYNLONTA + COLUMVI for the treatment of patients with 2nd-line relapsed/refractory DLBCL. Additional results from the phase 1b study, using ZYNLONTA + COLUMVI for the treatment of patients with 2nd-line relapsed/refractory DLBCL, to be released in the 1st half of 2025. The seven major Diffuse Large B-cell Lymphoma markets are expected to reach $5.25 billion by 2034.

Neutral

PRNewsWire

2 weeks ago

ADC Therapeutics Announces Positive Initial Data from LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Bispecific Antibody in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma

ZYNLONTA in combination with glofitamab demonstrated clinically meaningful benefit with 94% best ORR and 72% CR rate Safety data show no dose-limiting toxicities (DLTs), no high-grade cytokine release syndrome (CRS) or high-grade immune effector cell-associated neurotoxicity syndrome (ICANS) across all patients Company to host conference call today at 8:30 a.m. EST LAUSANNE, Switzerland , Dec. 11, 2024 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced positive initial data from the LOTIS-7 Phase 1b open-label clinical trial evaluating the safety and efficacy of ZYNLONTA® in combination with the bispecific antibody glofitamab (COLUMVI™) in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL).

$ADC Therapeutics Announces Positive Initial Data from LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Bispecific Antibody in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma$

Neutral

PRNewsWire

2 weeks ago

ADC Therapeutics Announces The Lancet Haematology Publication of Data from Investigator-Initiated Trial Evaluating ZYNLONTA® in Combination with Rituximab to Treat Relapsed/Refractory Follicular Lymphoma

Publication follows oral presentation at the American Society of Hematology (ASH) Annual Meeting Combination in r/r follicular lymphoma shows best ORR of 97% and CR rate of 77% with 12-month PFS of 95% Additional IIT data also presented at ASH on ZYNLONTA monotherapy in marginal zone lymphoma shows ORR of 91% and 70% CR LAUSANNE, Switzerland , Dec. 9, 2024 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced updated data from the investigator-initiated Phase 2 clinical trial evaluating ZYNLONTA® (loncastuximab tesirine-lpyl) in combination with rituximab to treat relapsed or refractory (r/r) follicular lymphoma (FL) were published in the December issue of The Lancet Haematology, following an oral presentation of the data at the recent 66th American Society of Hematology (ASH) Annual Meeting and Exposition. "We are excited by the publication of these results in The Lancet Haematology demonstrating ZYNLONTA's robust clinical activity in follicular lymphoma, particularly in patients classified as high-risk POD24 and those with high tumor burden where there remains significant unmet need," said Mohamed Zaki, MD, PhD, Chief Medical Officer of ADC Therapeutics.

$ADC Therapeutics Announces The Lancet Haematology Publication of Data from Investigator-Initiated Trial Evaluating ZYNLONTA® in Combination with Rituximab to Treat Relapsed/Refractory Follicular Lymphoma$